

Prostate Cancer Drugs Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type

<https://marketpublishers.com/r/PD9C6A315353EN.html>

Date: September 2025

Pages: 102

Price: US\$ 3,200.00 (Single User License)

ID: PD9C6A315353EN

Abstracts

Prostate Cancer Drugs Market Summary

The prostate cancer drugs market is a vital segment of the global pharmaceutical industry, addressing the treatment needs of one of the most prevalent cancers among men. Prostate cancer drugs encompass a range of therapies, including hormonal treatments, androgen receptor inhibitors, and chemotherapies, designed to manage localized, advanced, or metastatic prostate cancer. The market is characterized by significant research and development (R&D) efforts, driven by the increasing incidence of prostate cancer, particularly in aging populations, and the demand for targeted therapies with improved efficacy and safety profiles. By 2025, the global prostate cancer drugs market is estimated to be valued between USD 15 billion and USD 25 billion, with a projected compound annual growth rate (CAGR) of 0.8% to 1.6% through 2030. This modest growth reflects a mature market facing patent expirations and generic competition, balanced by steady demand due to rising disease prevalence and ongoing innovation. Prostate cancer drugs target various stages of the disease, from early-stage localized cancer to metastatic castration-resistant prostate cancer (mCRPC). Key drug classes include androgen receptor inhibitors (e.g., enzalutamide, apalutamide, darolutamide), androgen synthesis inhibitors (e.g., abiraterone acetate), and chemotherapies (e.g., cabazitaxel). These therapies aim to reduce testosterone levels or block androgen signaling, which drives prostate cancer growth. The industry is shaped by the high cost of branded drugs, complex clinical development processes, and the growing availability of generics following patent expirations for blockbuster drugs like Astellas Pharma's Xtandi (enzalutamide) and Johnson & Johnson's Zytiga (abiraterone acetate). Advances in precision medicine, combination therapies, and novel drug delivery systems are driving innovation, while regulatory scrutiny and pricing

pressures influence market dynamics. The market is also supported by increasing awareness, improved diagnostics, and a growing emphasis on personalized treatment approaches.

Regional Market Trends

The prostate cancer drugs market varies across regions, influenced by healthcare infrastructure, disease prevalence, and access to advanced therapies.

North America: The United States dominates this region, driven by high healthcare spending, advanced diagnostics, and widespread adoption of novel therapies. The region's CAGR is estimated at 0.5%–1.3% through 2030, reflecting a mature market with stable demand but increasing generic penetration due to patent expirations.

Europe: Germany, France, and the United Kingdom are key markets, with a CAGR of 0.7%–1.5%. Growth is supported by aging populations and robust healthcare systems, but pricing pressures and generic competition limit expansion.

Asia-Pacific: Japan and China lead this region, with a CAGR of 1.0%–2.0%. Japan's advanced healthcare system drives demand for premium therapies, while China's growing middle class and improving healthcare access boost market growth. India shows potential due to rising cancer awareness.

Latin America: Brazil and Mexico are key markets, with a CAGR of 0.8%–1.8%. Growth is driven by increasing healthcare access and rising prostate cancer incidence, though economic constraints and reliance on generics temper expansion.

Middle East and Africa (MEA): The region, including Saudi Arabia and South Africa, has a CAGR of 0.9%–2.0%. Growth is supported by improving healthcare infrastructure, but limited access to branded therapies and affordability issues constrain market potential.

Type Analysis

The prostate cancer drugs market is segmented by drug type, each with distinct

characteristics and growth trends.

Enzalutamide: Marketed as Xtandi by Astellas Pharma, enzalutamide is a leading androgen receptor inhibitor with 2024 revenues of USD 6–7 billion.

Apalutamide: Sold as Erleada by Johnson & Johnson, apalutamide generated USD 2.5–3.5 billion in 2024.

Darolutamide: Marketed as Nubeqa by Bayer, darolutamide generated USD 1–2 billion in 2024.

Abiraterone Acetate: Sold as Zytiga by Johnson & Johnson, abiraterone acetate generated USD 0.6–0.7 billion in 2024.

Cabazitaxel: Marketed as Jevtana by Sanofi, cabazitaxel generated USD 0.3 billion in 2024.

Others: Including hormonal therapies like goserelin (Zoladex by AstraZeneca) and emerging drugs, driven by generics and novel therapies in development.

Company Profiles

Bayer: Markets Nubeqa (darolutamide), generating USD 1–2 billion in 2024. Its long patent life (2030–2035) supports growth, and Bayer's global commercial strength ensures market presence.

Astellas Pharma: Leads with Xtandi (enzalutamide), generating USD 6–7 billion in 2024. Despite patent expiration, its strong market share sustains revenue.

Johnson & Johnson: Markets Zytiga (abiraterone acetate) and Erleada (apalutamide), with combined 2024 revenues of USD 3.1–4.2 billion. Its focus on innovation supports its leadership position.

Sanofi: Markets Jevtana (cabazitaxel), generating USD 0.3 billion in 2024. Generic competition limits growth, but Sanofi's oncology portfolio remains robust.

AbbVie: Markets Lupron (leuprolide acetate), a hormonal therapy with generic

competition post-patent expiration, focusing on cost-effective treatment options.

AstraZeneca: Markets Zoladex (goserelin), generating USD 1–2 billion in 2024, with steady demand in hormonal therapy applications.

Industry Value Chain Analysis

The prostate cancer drugs value chain begins with R&D, involving drug discovery, clinical trials, and regulatory approvals to develop targeted therapies. Manufacturing involves producing active pharmaceutical ingredients (APIs) and finished dosage forms under stringent quality standards. Distribution leverages global supply chains, with companies partnering with wholesalers and specialty pharmacies to ensure availability in hospitals and clinics. Marketing targets oncologists and urologists, emphasizing clinical benefits and patient outcomes.

Healthcare providers prescribe these drugs to patients, who access them through pharmacies or treatment centers. Pharmacovigilance ensures ongoing safety monitoring, while payers influence demand through reimbursement policies. The value chain is highly integrated, with leading companies controlling R&D, manufacturing, and commercialization to maximize efficiency and market share.

Opportunities and Challenges

Opportunities:

Rising Disease Prevalence: Increasing prostate cancer incidence, particularly in aging populations, drives demand for effective therapies.

Emerging Markets: Expanding healthcare access in Asia-Pacific and Latin America offers growth potential for branded and generic drugs.

Precision Medicine: Advances in biomarkers and combination therapies enhance treatment efficacy and market appeal.

Pipeline Innovation: Novel therapies and drug delivery systems in development support long-term growth.

Challenges:

Patent Expirations: Expirations for drugs like Xtandi and Zytiga increase generic competition, pressuring revenues.

Pricing Pressures: Cost containment by payers and healthcare systems limits profitability, particularly in Europe.

Regulatory Barriers: Stringent approval processes for new drugs increase development costs and market entry challenges.

Competition from Alternatives: Emerging therapies, such as immunotherapies and radiopharmaceuticals, may challenge market share.

Contents

CHAPTER 1 EXECUTIVE SUMMARY

CHAPTER 2 ABBREVIATION AND ACRONYMS

CHAPTER 3 PREFACE

3.1 Research Scope

3.2 Research Sources

3.2.1 Data Sources

3.2.2 Assumptions

3.3 Research Method

Chapter Four Market Landscape

4.1 Market Overview

4.2 Classification/Types

4.3 Application/End Users

CHAPTER 5 MARKET TREND ANALYSIS

5.1 Introduction

5.2 Drivers

5.3 Restraints

5.4 Opportunities

5.5 Threats

CHAPTER 6 INDUSTRY CHAIN ANALYSIS

6.1 Upstream/Suppliers Analysis

6.2 Prostate Cancer Drugs Analysis

6.2.1 Technology Analysis

6.2.2 Cost Analysis

6.2.3 Market Channel Analysis

6.3 Downstream Buyers/End Users

CHAPTER 7 LATEST MARKET DYNAMICS

7.1 Latest News

7.2 Merger and Acquisition

- 7.3 Planned/Future Project
- 7.4 Policy Dynamics

CHAPTER 8 HISTORICAL AND FORECAST PROSTATE CANCER DRUGS MARKET IN NORTH AMERICA (2020-2030)

- 8.1 Prostate Cancer Drugs Market Size
- 8.2 Prostate Cancer Drugs Market by End Use
- 8.3 Competition by Players/Suppliers
- 8.4 Prostate Cancer Drugs Market Size by Type
- 8.5 Key Countries Analysis
 - 8.5.1 United States
 - 8.5.2 Canada
 - 8.5.3 Mexico

CHAPTER 9 HISTORICAL AND FORECAST PROSTATE CANCER DRUGS MARKET IN SOUTH AMERICA (2020-2030)

- 9.1 Prostate Cancer Drugs Market Size
- 9.2 Prostate Cancer Drugs Market by End Use
- 9.3 Competition by Players/Suppliers
- 9.4 Prostate Cancer Drugs Market Size by Type
- 9.5 Key Countries Analysis
 - 9.5.1 Brazil
 - 9.5.2 Argentina

CHAPTER 10 HISTORICAL AND FORECAST PROSTATE CANCER DRUGS MARKET IN ASIA & PACIFIC (2020-2030)

- 10.1 Prostate Cancer Drugs Market Size
- 10.2 Prostate Cancer Drugs Market by End Use
- 10.3 Competition by Players/Suppliers
- 10.4 Prostate Cancer Drugs Market Size by Type
- 10.5 Key Countries Analysis
 - 10.5.1 China
 - 10.5.2 India
 - 10.5.3 Japan
 - 10.5.4 South Korea
 - 10.5.5 Southeast Asia

10.5.6 Australia

CHAPTER 11 HISTORICAL AND FORECAST PROSTATE CANCER DRUGS MARKET IN EUROPE (2020-2030)

- 11.1 Prostate Cancer Drugs Market Size
- 11.2 Prostate Cancer Drugs Market by End Use
- 11.3 Competition by Players/Suppliers
- 11.4 Prostate Cancer Drugs Market Size by Type
- 11.5 Key Countries Analysis
 - 11.5.1 Germany
 - 11.5.2 France
 - 11.5.3 United Kingdom
 - 11.5.4 Italy
 - 11.5.5 Spain
 - 11.5.6 Belgium
 - 11.5.7 Netherlands
 - 11.5.8 Austria
 - 11.5.9 Poland
 - 11.5.10 Russia

CHAPTER 12 HISTORICAL AND FORECAST PROSTATE CANCER DRUGS MARKET IN MEA (2020-2030)

- 12.1 Prostate Cancer Drugs Market Size
- 12.2 Prostate Cancer Drugs Market by End Use
- 12.3 Competition by Players/Suppliers
- 12.4 Prostate Cancer Drugs Market Size by Type

CHAPTER 13 SUMMARY FOR GLOBAL PROSTATE CANCER DRUGS MARKET (2020-2025)

- 13.1 Prostate Cancer Drugs Market Size
- 13.2 Prostate Cancer Drugs Market by End Use
- 13.3 Competition by Players/Suppliers
- 13.4 Prostate Cancer Drugs Market Size by Type

CHAPTER 14 GLOBAL PROSTATE CANCER DRUGS MARKET FORECAST (2025-2030)

- 14.1 Prostate Cancer Drugs Market Size Forecast
- 14.2 Prostate Cancer Drugs Application Forecast
- 14.3 Competition by Players/Suppliers
- 14.4 Prostate Cancer Drugs Type Forecast

CHAPTER 15 ANALYSIS OF GLOBAL KEY VENDORS

15.1 Bayer

- 15.1.1 Company Profile
- 15.1.2 Main Business and Prostate Cancer Drugs Information
- 15.1.3 SWOT Analysis of Bayer
- 15.1.4 Bayer Prostate Cancer Drugs Revenue, Gross Margin and Market Share (2020-2025)

15.2 Astellas Pharma

- 15.2.1 Company Profile
- 15.2.2 Main Business and Prostate Cancer Drugs Information
- 15.2.3 SWOT Analysis of Astellas Pharma
- 15.2.4 Astellas Pharma Prostate Cancer Drugs Revenue, Gross Margin and Market Share (2020-2025)

15.3 Johnson & Johnson

- 15.3.1 Company Profile
- 15.3.2 Main Business and Prostate Cancer Drugs Information
- 15.3.3 SWOT Analysis of Johnson & Johnson
- 15.3.4 Johnson & Johnson Prostate Cancer Drugs Revenue, Gross Margin and Market Share (2020-2025)

15.4 Sanofi

- 15.4.1 Company Profile
- 15.4.2 Main Business and Prostate Cancer Drugs Information
- 15.4.3 SWOT Analysis of Sanofi
- 15.4.4 Sanofi Prostate Cancer Drugs Revenue, Gross Margin and Market Share (2020-2025)

15.5 AbbVie

- 15.5.1 Company Profile
- 15.5.2 Main Business and Prostate Cancer Drugs Information
- 15.5.3 SWOT Analysis of AbbVie
- 15.5.4 AbbVie Prostate Cancer Drugs Revenue, Gross Margin and Market Share (2020-2025)

15.6 AstraZeneca

- 15.6.1 Company Profile
- 15.6.2 Main Business and Prostate Cancer Drugs Information
- 15.6.3 SWOT Analysis of AstraZeneca
- 15.6.4 AstraZeneca Prostate Cancer Drugs Revenue, Gross Margin and Market Share (2020-2025)
- 15.7 Viatris
 - 15.7.1 Company Profile
 - 15.7.2 Main Business and Prostate Cancer Drugs Information
 - 15.7.3 SWOT Analysis of Viatris
 - 15.7.4 Viatris Prostate Cancer Drugs Revenue, Gross Margin and Market Share (2020-2025)
- 15.8 Teva Pharmaceuticals
 - 15.8.1 Company Profile
 - 15.8.2 Main Business and Prostate Cancer Drugs Information
 - 15.8.3 SWOT Analysis of Teva Pharmaceuticals
 - 15.8.4 Teva Pharmaceuticals Prostate Cancer Drugs Revenue, Gross Margin and Market Share (2020-2025)
- 15.9 Dr. Reddy's
 - 15.9.1 Company Profile
 - 15.9.2 Main Business and Prostate Cancer Drugs Information
 - 15.9.3 SWOT Analysis of Dr. Reddy's
 - 15.9.4 Dr. Reddy's Prostate Cancer Drugs Revenue, Gross Margin and Market Share (2020-2025)

Please ask for sample pages for full companies list

Tables & Figures

TABLES AND FIGURES

Table Abbreviation and Acronyms

Table Research Scope of Prostate Cancer Drugs Report

Table Data Sources of Prostate Cancer Drugs Report

Table Major Assumptions of Prostate Cancer Drugs Report

Figure Market Size Estimated Method

Figure Major Forecasting Factors

Figure Prostate Cancer Drugs Picture

Table Prostate Cancer Drugs Classification

Table Prostate Cancer Drugs Applications

Table Drivers of Prostate Cancer Drugs Market

Table Restraints of Prostate Cancer Drugs Market

Table Opportunities of Prostate Cancer Drugs Market

Table Threats of Prostate Cancer Drugs Market

Table Raw Materials Suppliers

Table Different Production Methods of Prostate Cancer Drugs

Table Cost Structure Analysis of Prostate Cancer Drugs

Table Key End Users

Table Latest News of Prostate Cancer Drugs Market

Table Merger and Acquisition

Table Planned/Future Project of Prostate Cancer Drugs Market

Table Policy of Prostate Cancer Drugs Market

Table 2020-2030 North America Prostate Cancer Drugs Market Size

Figure 2020-2030 North America Prostate Cancer Drugs Market Size and CAGR

Table 2020-2030 North America Prostate Cancer Drugs Market Size by Application

Table 2020-2025 North America Prostate Cancer Drugs Key Players Revenue

Table 2020-2025 North America Prostate Cancer Drugs Key Players Market Share

Table 2020-2030 North America Prostate Cancer Drugs Market Size by Type

Table 2020-2030 United States Prostate Cancer Drugs Market Size

Table 2020-2030 Canada Prostate Cancer Drugs Market Size

Table 2020-2030 Mexico Prostate Cancer Drugs Market Size

Table 2020-2030 South America Prostate Cancer Drugs Market Size

Figure 2020-2030 South America Prostate Cancer Drugs Market Size and CAGR

Table 2020-2030 South America Prostate Cancer Drugs Market Size by Application

Table 2020-2025 South America Prostate Cancer Drugs Key Players Revenue

Table 2020-2025 South America Prostate Cancer Drugs Key Players Market Share

Table 2020-2030 South America Prostate Cancer Drugs Market Size by Type

Table 2020-2030 Brazil Prostate Cancer Drugs Market Size
Table 2020-2030 Argentina Prostate Cancer Drugs Market Size
Table 2020-2030 Asia & Pacific Prostate Cancer Drugs Market Size
Figure 2020-2030 Asia & Pacific Prostate Cancer Drugs Market Size and CAGR
Table 2020-2030 Asia & Pacific Prostate Cancer Drugs Market Size by Application
Table 2020-2025 Asia & Pacific Prostate Cancer Drugs Key Players Revenue
Table 2020-2025 Asia & Pacific Prostate Cancer Drugs Key Players Market Share
Table 2020-2030 Asia & Pacific Prostate Cancer Drugs Market Size by Type
Table 2020-2030 China Prostate Cancer Drugs Market Size
Table 2020-2030 India Prostate Cancer Drugs Market Size
Table 2020-2030 Japan Prostate Cancer Drugs Market Size
Table 2020-2030 South Korea Prostate Cancer Drugs Market Size
Table 2020-2030 Southeast Asia Prostate Cancer Drugs Market Size
Table 2020-2030 Australia Prostate Cancer Drugs Market Size
Table 2020-2030 Europe Prostate Cancer Drugs Market Size
Figure 2020-2030 Europe Prostate Cancer Drugs Market Size and CAGR
Table 2020-2030 Europe Prostate Cancer Drugs Market Size by Application
Table 2020-2025 Europe Prostate Cancer Drugs Key Players Revenue
Table 2020-2025 Europe Prostate Cancer Drugs Key Players Market Share
Table 2020-2030 Europe Prostate Cancer Drugs Market Size by Type
Table 2020-2030 Germany Prostate Cancer Drugs Market Size
Table 2020-2030 France Prostate Cancer Drugs Market Size
Table 2020-2030 United Kingdom Prostate Cancer Drugs Market Size
Table 2020-2030 Italy Prostate Cancer Drugs Market Size
Table 2020-2030 Spain Prostate Cancer Drugs Market Size
Table 2020-2030 Belgium Prostate Cancer Drugs Market Size
Table 2020-2030 Netherlands Prostate Cancer Drugs Market Size
Table 2020-2030 Austria Prostate Cancer Drugs Market Size
Table 2020-2030 Poland Prostate Cancer Drugs Market Size
Table 2020-2030 Russia Prostate Cancer Drugs Market Size
Table 2020-2030 MEA Prostate Cancer Drugs Market Size
Figure 2020-2030 MEA Prostate Cancer Drugs Market Size and CAGR
Table 2020-2030 MEA Prostate Cancer Drugs Market Size by Application
Table 2020-2025 MEA Prostate Cancer Drugs Key Players Revenue
Table 2020-2025 MEA Prostate Cancer Drugs Key Players Market Share
Table 2020-2030 MEA Prostate Cancer Drugs Market Size by Type
Table 2020-2025 Global Prostate Cancer Drugs Market Size by Region
Table 2020-2025 Global Prostate Cancer Drugs Market Size Share by Region
Table 2020-2025 Global Prostate Cancer Drugs Market Size by Application

Table 2020-2025 Global Prostate Cancer Drugs Market Share by Application
Table 2020-2025 Global Prostate Cancer Drugs Key Vendors Revenue
Figure 2020-2025 Global Prostate Cancer Drugs Market Size and Growth Rate
Table 2020-2025 Global Prostate Cancer Drugs Key Vendors Market Share
Table 2020-2025 Global Prostate Cancer Drugs Market Size by Type
Table 2020-2025 Global Prostate Cancer Drugs Market Share by Type
Table 2025-2030 Global Prostate Cancer Drugs Market Size by Region
Table 2025-2030 Global Prostate Cancer Drugs Market Size Share by Region
Table 2025-2030 Global Prostate Cancer Drugs Market Size by Application
Table 2025-2030 Global Prostate Cancer Drugs Market Share by Application
Table 2025-2030 Global Prostate Cancer Drugs Key Vendors Revenue
Figure 2025-2030 Global Prostate Cancer Drugs Market Size and Growth Rate
Table 2025-2030 Global Prostate Cancer Drugs Key Vendors Market Share
Table 2025-2030 Global Prostate Cancer Drugs Market Size by Type
Table 2025-2030 Prostate Cancer Drugs Global Market Share by Type
Table Bayer Information
Table SWOT Analysis of Bayer
Table 2020-2025 Bayer Prostate Cancer Drugs Revenue Gross Profit Margin
Figure 2020-2025 Bayer Prostate Cancer Drugs Revenue and Growth Rate
Figure 2020-2025 Bayer Prostate Cancer Drugs Market Share
Table Astellas Pharma Information
Table SWOT Analysis of Astellas Pharma
Table 2020-2025 Astellas Pharma Prostate Cancer Drugs Revenue Gross Profit Margin
Figure 2020-2025 Astellas Pharma Prostate Cancer Drugs Revenue and Growth Rate
Figure 2020-2025 Astellas Pharma Prostate Cancer Drugs Market Share
Table Johnson & Johnson Information
Table SWOT Analysis of Johnson & Johnson
Table 2020-2025 Johnson & Johnson Prostate Cancer Drugs Revenue Gross Profit Margin
Figure 2020-2025 Johnson & Johnson Prostate Cancer Drugs Revenue and Growth Rate
Figure 2020-2025 Johnson & Johnson Prostate Cancer Drugs Market Share
Table Sanofi Information
Table SWOT Analysis of Sanofi
Table 2020-2025 Sanofi Prostate Cancer Drugs Revenue Gross Profit Margin
Figure 2020-2025 Sanofi Prostate Cancer Drugs Revenue and Growth Rate
Figure 2020-2025 Sanofi Prostate Cancer Drugs Market Share
Table AbbVie Information
Table SWOT Analysis of AbbVie

Table 2020-2025 AbbVie Prostate Cancer Drugs Revenue Gross Profit Margin

Figure 2020-2025 AbbVie Prostate Cancer Drugs Revenue and Growth Rate

Figure 2020-2025 AbbVie Prostate Cancer Drugs Market Share

Table AstraZeneca Information

Table SWOT Analysis of AstraZeneca

Table 2020-2025 AstraZeneca Prostate Cancer Drugs Revenue Gross Profit Margin

Figure 2020-2025 AstraZeneca Prostate Cancer Drugs Revenue and Growth Rate

Figure 2020-2025 AstraZeneca Prostate Cancer Drugs Market Share

Table Viatrix Information

Table SWOT Analysis of Viatrix

Table 2020-2025 Viatrix Prostate Cancer Drugs Revenue Gross Profit Margin

Figure 2020-2025 Viatrix Prostate Cancer Drugs Revenue and Growth Rate

Figure 2020-2025 Viatrix Prostate Cancer Drugs Market Share

Table Teva Pharmaceuticals Information

Table SWOT Analysis of Teva Pharmaceuticals

Table 2020-2025 Teva Pharmaceuticals Prostate Cancer Drugs Revenue Gross Profit Margin

Figure 2020-2025 Teva Pharmaceuticals Prostate Cancer Drugs Revenue and Growth Rate

Figure 2020-2025 Teva Pharmaceuticals Prostate Cancer Drugs Market Share

Table Dr. Reddy's Information

Table SWOT Analysis of Dr. Reddy's

Table 2020-2025 Dr. Reddy's Prostate Cancer Drugs Revenue Gross Profit Margin

Figure 2020-2025 Dr. Reddy's Prostate Cancer Drugs Revenue and Growth Rate

Figure 2020-2025 Dr. Reddy's Prostate Cancer Drugs Market Share

.....

I would like to order

Product name: Prostate Cancer Drugs Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type

Product link: <https://marketpublishers.com/r/PD9C6A315353EN.html>

Price: US\$ 3,200.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/PD9C6A315353EN.html>